Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Eurofins Scientific    ERF   FR0014000MR3


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eurofins Scientific : Transplant Diagnostics Expands Footprint in Hawaii through the acquisition of Hawaii Cellular Therapy and Transplant Laboratory (HCTTL) New location brings a comprehensive approach to Pre- and Post-Transplant testing to the island and supports the advancement of transplant patient care

10/23/2020 | 04:50am EST
Thursday, October 22, 2020

Eurofins' US Transplant Diagnostics is proud to announce the successful acquisition of the Hawaii Cellular Therapy and Transplant Laboratory (HCTTL). HCTTL will merge with Eurofins VRL, a market leader in US pre-transplant testing, and expand VRL's substantial US geographic footprint.

The addition of this highly regarded and long-standing pillar of the Hawaiian transplant community will further increase VRL's network of laboratories that are now located in 11 states, serving Organ Procurement Organizations, Tissue Banks, and commercial companies needing testing for donated biological materials.

'The laboratory plays a critical role in providing access to therapy by supporting the solid organ transplant program at The Queen's Medical Center, as well as Legacy of Life Hawaii, the State's organ and tissue donation program,' Professor Randal K. Wada, M.D., University of Hawaii said in a statement.

'We are thrilled that under Eurofins VRL, the laboratory will be able to take full advantage of state of the art technologies and be well-positioned to expand services and capacity in the future,' Dr. Wada added.

The acquisition of HCTTL aligns nicely to the Eurofins Transplant Diagnostics strategy of expanding and strengthening the transplant network and maintaining its leadership position in the pre- and post-transplantation organ testing market.

With the combined transplant diagnostics portfolio of Viracor-Eurofins laboratory and Transplant Genomics innovative testing of subclinical rejection detection testing, Eurofins' US Transplant Diagnostics will advance transplant care and aid organ procurement organizations within the region. Please visit http://www.vrl-eurofins.com/for more information.


Kimberly Elliott



About VRL

With over twenty five years of experience in donor eligibility testing, VRL-Eurofins has eleven high complexity testing laboratories located in Denver, Colorado; Dallas, Texas; Boston, Massachusetts; Atlanta, Georgia; Los Angeles, California; Minnesota, Minneapolis; Philadelphia, Pennsylvania; San Ramon; California, Cincinnati, Ohio, Winston-Salem, North Carolina and Honolulu, Hawaii. VRL-Eurofins' focus is performing Donor Eligibility Screening and Microbiology Testing, using the most appropriate regulated testing technologies for the transplant and medical communities. VRL has brought together a diverse professional team with experience in testing, quality, regulatory, and customer service.

About Viracor

With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams and reference laboratories get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves. Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.viracor-eurofins.com/.

About Eurofins - the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter 'Eurofins' or 'the Group'), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).


Eurofins Scientific SE published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2020 08:49:07 UTC

© Publicnow 2020
01/18EUROFINS SCIENTIFIC : Bioanalytical Services launches Surrogate Virus Neutralizi..
01/15Eurofins Launches New Test, Increased Capacity to Detect SARS-CoV-2 Variants
01/15EUROFINS : the global leader in analytical testing, expands worldwide face mask ..
01/15EUROFINS SCIENTIFIC : Launches New Tests and Massive Capacity for Detecting and ..
01/11EUROFINS SCIENTIFIC : Anti-COVID-19 System Gets Emergency Response Validation PT..
01/11EUROFINS SCIENTIFIC : GeneScan Technologies Announces AOAC PTM Accreditation for..
2020EUROFINS SCIENTIFIC : Launches Full-Length COVID-19Viral Genome Sequencing Servi..
2020EUROFINS SCIENTIFIC : Genomics Launches Cost-Effective SARS-CoV-2 full-length Vi..
2020EUROFINS CEREP : Launches PCR COVID-19 Self-Test In Germany, Spain
2020EUROFINS SCIENTIFIC : launches COVID-19 PCR tests with at-home self-sampling opt..
More news
Sales 2020 5 270 M 6 414 M 6 414 M
Net income 2020 405 M 493 M 493 M
Net Debt 2020 2 816 M 3 427 M 3 427 M
P/E ratio 2020 37,6x
Yield 2020 0,65%
Capitalization 14 882 M 18 116 M 18 112 M
EV / Sales 2020 3,36x
EV / Sales 2021 3,10x
Nbr of Employees 48 000
Free-Float 66,7%
Duration : Period :
Eurofins Scientific Technical Analysis Chart | ERF | FR0014000MR3 | MarketScreener
Technical analysis trends EUROFINS SCIENTIFIC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 73,97 €
Last Close Price 78,00 €
Spread / Highest target 9,10%
Spread / Average Target -5,16%
Spread / Lowest Target -51,0%
EPS Revisions
Managers and Directors
Gilles J. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Andreas König Chief Information Officer
Yves-Loïc Martin Non-Executive Director
Valérie Hanote Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SQUARE, INC.0.91%99 035
FISERV, INC.-4.31%73 044